Aug. 15, 2019: In this month's Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights advances in a variety of cancer types, including breast, ovarian, and prostate cancer; research into genetic mutations that could lead to better treatments for individual patients; and research involving the financial burdens that weigh upon patients and their families. Read More
July 20, 2019: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights some of the outdoor events that support cancer research. Meanwhile, researchers indoors are making progress with new treatments that show improvements in survival for certain cancers while working toward a better understanding of cancers with low survival rates. Read More
July 10, 2019: Nasser Hanna, MD, a thoracic oncology specialist at the Indiana University Melvin and Bren Simon Cancer Center, has been appointed to the Big Ten Cancer Research Consortium (Big Ten CRC) Steering Committee. As the representative for Indiana University, Dr. Hanna will work with the Steering Committee to shape research priorities for the Big Ten CRC. “I’m honored and excited and looking forward to getting started,” Dr. Hanna said. “I’ve enjoyed my work with the Big Ten CRC and our member institutions. I’d like to continue to build on the efforts to reduce timelines for Read More
July 1, 2019: Investigator Spotlight: Imagine having surgery to remove a tumor, and by the time you’ve recovered from the operation, your oncologist has determined a specific drug regimen that is targeted to treat your cancer. “If you get diagnosed with a bacterial infection, we take a culture, grow the bacteria in the lab, and treat the cultures with antibiotics,” said Dustin Deming, MD, a gastrointestinal oncologist and researcher with the UW Carbone Cancer Center. “This helps us learn what antibiotic will best treat an infection. Why can’t we do the... Read More
June 24, 2019: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) focuses on immunotherapy treatments which are quickly growing to be successful treatments for cancer. There is also growing research on specific cancers and how they affect different populations based on several demographics. Read More
June 1, 2019: Investigator Spotlight: Robert Kratzke, MD, University of Minnesota Research interests: I am a medical oncologist with a particular interest in lung cancer and mesothelioma. In my laboratory we are currently looking at the use of viruses for cancer therapy. In particular, the vesicular stomatitis virus (VSV) interests us as it preferentially infects cancer cells without causing disease in humans. We have shown that injecting the virus at one tumor will rapidly lead to infection in other tumor sites throughout the body. Also, the infection of the cancer cells not only kills malignant cells, it elicits an immune response that helps attack surrounding cancer cells without harming normal cells. Finally, this enhanced immune response makes the infected cancer cells more... Read More
May 30, 2019: The Cancer Center at Illinois (CCIL) has joined the Big Ten Cancer Research Consortium (Big Ten CRC). Located at the University of Illinois at Urbana-Champaign, the CCIL develops new insights, tools, and technologies to fight cancer and moves those advances into clinical practice. The CCIL unites historic campus strengths in basic science and engineering to develop new ways to prevent, diagnose, and treat cancer, enabling people to live cancer-free lives. Read More
May 30, 2019: Two Big Ten Cancer Research Consortium studies, BTCRC-LUN16-081 and BTCRC-ESO14-012, will be presented during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, in Chicago. BTCRC-LUN16-081, a phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer (NSCLC), will be featured during a poster session on Sunday, June 2. The study is led by Greg Durm, MD, of the Indiana University Melvin and Bren Simon Cancer Center. Read More
May 29, 2019: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) has joined the Big Ten Cancer Research Consortium (Big Ten CRC). Through membership in the consortium, cancer researchers from The Ohio State University may participate in the Big Ten CRC’s Clinical Trial Working Groups, submit letters of intent (LOIs) to the working groups for consideration as Big Ten studies, and collaborate with researchers from other Big Ten cancer centers on clinical trials. Based in Columbus, Ohio, the OSUCCC – James is the... Read More
Indiana University researchers are leading a new Big Ten Cancer Research Consortium study that will test consolidation immunotherapy in unresectable Stage III non-small cell lung cancer.
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube